Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date. Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs)…
“We are pleased with our team’s progress in pioneering the development of promising image-guided, lead-based, alpha particle therapies.” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics…
Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor…
First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01… Preliminary data readout from dose escalation study expected Q4 2023…
• Phase I/2a clinical trials initiated: VMT-𝛼-NET for neuroendocrine tumors, and VMT01 for melanoma…
“We are delighted to announce the expansion of our collaboration with GT MedTech to increase our manufacturing in support of their objective of bringing GammaTile Therapy to more patients…
The presentation entitled Prostate Brachytherapy with Cs-131: Long Term Results Compared to Published SBRT Data, by authors Mohammed A. Mohammed, MD, Ronald M. Benoit, Sushil Beriwal, MD, and Ryan P. Smith, MD was presented by Ryan P. Smith…
VMT-α-NET for neuroendocrine cancers and VMT01 for melanoma are both entering therapeutic trials under IND at leading US institutions…
Four presentations from Perspective Therapeutics’ scientists and collaborators will explore the First in Human clinical imaging data from the company’s MC1R-targeted theranostic product…
©2023. All rights reserved. Terms & Privacy | Privacy Policy
